Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Dr Paul Overton

Dr Paul Overton joined Sygnature Discovery in June 2020 as Chief Commercial Officer and Executive Board Director.

He has over 20 years of business development experience in the pharmaceutical and biotechnology sectors delivering integrated development solutions. Paul has previously held roles in Eurofins BPT as Head of Europeans Sales, in Evotec as Global Head Business Development and in Aptuit as EVP Global Business and Corporate Development. After initially working in the research developing diagnostic assays and bioanalytical methods, he transitioned into a commercial career in the preclinical development space.

Dr Paul Overton has a degree in Applied Biological Sciences from Bristol and  a PhD in cellular immunology from Surrey University.

Latest News

View All

First patients dosed in Phase 1a clinical…

Sygnature Discovery Appoints Industry Leaders To Board…

Sygnature Discovery invests £3.75M in Compound Management…

Sygnature Discovery collaborates with Axol Bioscience to…